What is PRPO's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.04B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for PRPO?

P/E (TTM) is n/a and 52-week range is $16.40 to $33.63 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s PRPO figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for PRPO?

The company profile lists revenue (TTM) near $27M, net income (TTM) near $-122M, EPS (TTM) near $-0.68 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Precipio Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in New Haven, Connecticut, US, 1.8M shares outstanding, ISIN US74019L6020 when available from company profile and filing metadata.

Precipio Inc

$PRPO

Health Care · Health Care Providers & Services

IR Run Scenarios

$22.30

-1.28%

Precipio Inc

$PRPO

Health Care · Health Care Providers & Services

IR Run Scenarios

$22.30

-1.28%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Precipio, Inc.is a cancer diagnostics and reagent technology company, which provides diagnostic products and services to the oncology market. The company is headquartered in New Haven, Connecticut and currently employs 61 full-time employees. The company went IPO on 2000-07-18. The Company’s technologies include HemeScreen and IV-Cell. The HemeScreen panels test for the presence of various mutations. In developing HemeScreen, it focused on improving the economics of providing blood cancer diagnostic tests and reducing laboratory technician time consumed in the testing process. Its technology enables testing to be completed in one rapid scanning process. IV-Cell is a cell culture media that addresses the problem of diagnostic mistakes through the process of selective culturing. IV-Cell is a universal media that enables simultaneous culturing of all four hematopoietic cell lineages. Its product category includes Molecular Kits and IV-Cell Cytogenetics Media. The Molecular Kits include Quantitative MPN Panel, ABL1 Resistance Panel, and others. The Company’s laboratory and research and development (R&D) facilities are located in New Haven, Connecticut and Omaha, Nebraska.

Employees

57

Website

www.precipiodx.com/

IPO

2000-07-18

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)

Net income (TTM)

EPS (TTM)

P/E (TTM)

P/S (TTM)

Forward P/E

Forward P/S

EV / EBITDA

PEG (TTM)

FCF yield (TTM)

Gross margin (TTM)

Net margin (TTM)

Forward revenue growth (NTM)

Dividend / share (TTM)

Dividend yield (TTM)

Payout ratio (TTM)

Dividend growth (5Y)

Company context

Exchange

NASDAQ NMS - GLOBAL MARKET

ISIN

US74019L6020

Headquarters

New Haven, Connecticut, US

Shares outstanding

1.8M

NAICS sector

Manufacturing

Institutional ownership

17.71%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Precipio, Inc.is a cancer diagnostics and reagent technology company, which provides diagnostic products and services to the oncology market. The company is headquartered in New Haven, Connecticut and currently employs 61 full-time employees. The company went IPO on 2000-07-18. The Company’s technologies include HemeScreen and IV-Cell. The HemeScreen panels test for the presence of various mutations. In developing HemeScreen, it focused on improving the economics of providing blood cancer diagnostic tests and reducing laboratory technician time consumed in the testing process. Its technology enables testing to be completed in one rapid scanning process. IV-Cell is a cell culture media that addresses the problem of diagnostic mistakes through the process of selective culturing. IV-Cell is a universal media that enables simultaneous culturing of all four hematopoietic cell lineages. Its product category includes Molecular Kits and IV-Cell Cytogenetics Media. The Molecular Kits include Quantitative MPN Panel, ABL1 Resistance Panel, and others. The Company’s laboratory and research and development (R&D) facilities are located in New Haven, Connecticut and Omaha, Nebraska.

Employees

57

Website

www.precipiodx.com/

IPO

2000-07-18

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)